Abstract
Immunoproteasome is an emerging biological target that constitutes a key element not only in antigen presentation but also in T cell and cytokine regulation as well as cellular homeostasis. Respect to standard proteasome, the inducible expression and different sensitivity towards activity modulators of immunoproteasome render it a potential therapeutic target for tumours and central nervous system diseases. In this review we report the cutting edge studies for understanding when immunoproteasome expression is induced and how it regulates pivotal pathways involved in tumours and neuropathologies, including apoptosis and inflammation. We emphasize its role as a new pharmacological target by describing the recent medicinal chemistry efforts aimed at design selective small-molecule modulators of both standard- and immuno-proteasome forms. Finally, we also present an in silico model of the human immunoproteasome structure by the major molecular differences with the 20S standard proteasome and discuss the perspective for the design of novel specific smallmolecule modulators for the different proteasome isoforms.
Current Pharmaceutical Design
Title:Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Volume: 19 Issue: 4
Author(s): Elena Bellavista, Federico Andreoli, Marco Daniele Parenti, Morena Martucci, Aurelia Santoro, Stefano Salvioli, Miriam Capri, Agostino Baruzzi, Alberto Del Rio, Claudio Franceschi, Michele Mishto
Affiliation:
Abstract: Immunoproteasome is an emerging biological target that constitutes a key element not only in antigen presentation but also in T cell and cytokine regulation as well as cellular homeostasis. Respect to standard proteasome, the inducible expression and different sensitivity towards activity modulators of immunoproteasome render it a potential therapeutic target for tumours and central nervous system diseases. In this review we report the cutting edge studies for understanding when immunoproteasome expression is induced and how it regulates pivotal pathways involved in tumours and neuropathologies, including apoptosis and inflammation. We emphasize its role as a new pharmacological target by describing the recent medicinal chemistry efforts aimed at design selective small-molecule modulators of both standard- and immuno-proteasome forms. Finally, we also present an in silico model of the human immunoproteasome structure by the major molecular differences with the 20S standard proteasome and discuss the perspective for the design of novel specific smallmolecule modulators for the different proteasome isoforms.
Export Options
About this article
Cite this article as:
Stefano Salvioli, Miriam Capri, Agostino Baruzzi, Alberto Del Rio, Claudio Franceschi, Michele Mishto Elena Bellavista, Federico Andreoli, Marco Daniele Parenti, Morena Martucci, Aurelia Santoro,, Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?, Current Pharmaceutical Design 2013; 19 (4) . https://dx.doi.org/10.2174/1381612811306040702
DOI https://dx.doi.org/10.2174/1381612811306040702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.
Current Protein & Peptide Science Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes
Current Signal Transduction Therapy Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study
Current Medicinal Chemistry - Anti-Cancer Agents Novel Fluorescent Benzimidazoles: Synthesis, Characterization, Crystal Structure and Evaluation of Their Anticancer Properties
Letters in Organic Chemistry Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
Current Pharmaceutical Design Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery LC-HRMS and NMR Analysis of Lyophilized Acmella oleracea Capitula, Leaves and Stems
The Natural Products Journal An Active and Low-cost Microwave Imaging System for Detection of Breast Cancer Using Back Scattered Signal
Current Medical Imaging Contributions of the Interaction Between Dietary Protein and Gut Microbiota to Intestinal Health
Current Protein & Peptide Science COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Current Pharmaceutical Design Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies
Current Cancer Therapy Reviews Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Cadmium as an Endocrine Disruptor in the Reproductive System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulators of the microRNA Biogenesis Pathway via Arrayed Lentiviral Enabled RNAi Screening for Drug and Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Harnessing CD36 to Rein in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Evidence for the Involvement of Resistin in Inflammation and Cardiovascular Disease
Current Diabetes Reviews